82 / 144
82
PERGUNTAS & RESPOSTAS
EMD
- Edema Macular Diabético
Referências
1. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F et al. Guidelines for the Management
of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA).
Ophthalmologica. 2017;237(4):185-222.
2. Do DV, Nguyen QD, Vitti R et al. Intravitreal A`ibercept Injection in Macular Edema
Patients with and without Prior AntiVascular Endothelial Growth Factor Treatment Out-
comes from the Phase 3 Program. Ophthalmology.2016;123(4), 850-857.
3. Arevalo JF, Lasave AF,2 Wu L et al. Intravitreal bevacizumab for diabetic macular oede-
ma: 5-year results of the Pan-American Collaborative Retina study group. Br J Ophthal-
mol. 2016;100:1605-1610.
4. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled
trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic
macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130:972-9.
5. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab thera-
py for diabetic macular edema: the 36-month results from two phase III trials: RISE and
RIDE. Ophthalmology. 2013;120:2013-22.
6. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal a`ibercept for diabetic macu-
lar edema. Ophthalmology. 2014;121:2247-54.
7. Elman MJ, Ayala A, Bressler NM et al. Diabetic Retinopathy Clinical Research Network.
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser
treatment: %ve-year randomized trial results. Ophthalmology. 2015;122(2):375-381.
Fig. 1
DRCR.net(protocolo I): ganhos sustentados a 5 anos com redução
signi%cativa do números de injeções. Melhores resultados no grupo com
laser diferido (após 24 semanas).
Grá2co adaptado a partir do artigo de Elman et al.
7
, com a permissão da
Elsevier.